Janssen Biotech, a Johnson & Johnson company, has executed a license and development agreement for an investigational anti-cancer agent, daratumumab (HuMax-CD38), with Genmab.
Daratumumab is a human CD38 monoclonal antibody which is currently in Phase I/II studies in relapsed, refractory multiple myeloma and is expected to have potential in other cancer indications.
As per the deal, Genmab will grant worldwide license to develop and commercialize daratumumab as well as a backup human CD38 antibody to Janssen and is responsible to complete the GEN501 and GEN503 Phase I/II trials while Janssen will be responsible for all other development, clinical and regulatory filing activities.
Janssen Research & Development head William Hait said the firm has recognised the power of monoclonal antibodies in biologics.
"We look forward to applying that same expertise to daratumumab to help meet the needs of patients with multiple myeloma," Hait added.
Pursuant to the deal, Genmab earned an upfront payment and is eligible to receive additional payments based upon the achievement of certain development, regulatory and sales milestones.
Additionally, as a part of the transaction, which is subject to customary closing conditions, Johnson & Johnson Development, an affiliate of Janssen, will make an equity investment in Genmab.
